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INTRODUCTION
Alzheimer’s disease is a neurological illness resulting in the deterioration of brain
regions that control memory and cognitive function. Not only is there no cure or
effective treatment, but it is also degenerative, meaning that its severity only
worsens over time. Through years of neuroscience research, scientists have
discovered much of what happens in the brain during the onset of Alzheimer’s
disease and how this causes its symptoms, leading to various hypotheses including
the potential roles of temporal lobe atrophy, neurofibrillary tangles, and amyloid
plaques in its etiology and progression. Although Alzheimer’s disease affects
millions every day, many are unaware of how it impacts the human body
physiologically, emotionally, and psychosocially. This overwhelming lack of
general knowledge regarding the main characteristics, physiological causes, and
diagnostic criteria of this illness makes it difficult to recognize the presence of
Alzheimer’s disease within oneself, friends, and family members, which could in
turn stop patients from receiving necessary care and supervision. Therefore,
knowledge of the relationship between neuroscience and Alzheimer’s disease is
essential for proper diagnosis and treatment. The following literature review
explores research investigating the relationship between neuroscience and
Alzheimer’s disease and how this illness affects the body from many facets.

OVERVIEW
DEFINING CHARACTERISTICS AND DIAGNOSTIC CRITERIA
Various external symptoms must be present in order to classify cognitive decline
as Alzheimer’s disease. The need for diagnosis often goes unnoticed because not
only will the patient’s cognitive decline be attributed to old age, but their loved
ones are also unaware of how signs of healthy aging differ from that of Alzheimer’s
disease (Alzheimer’s Association, 2019). According to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), patients must
exhibit numerous symptoms including both a decline in memory and one of the
following cognitive defects: aphasia—loss of speech abilities, apraxia—loss of
motor skills, agnosia—loss of sensory processing, and trouble with executive
functioning (American Psychiatric Association, 2000, p. 157). As Alzheimer’s
disease progresses, these symptoms become more apparent, leading to diagnosis if
handled properly, which requires bringing patients to a primary care physician who
will obtain a medical and family history, conduct cognitive tests, and perform
physical and neurological examinations. Sometimes, medical professionals will
also order magnetic resonance imaging (MRI) scans to ensure that the patient’s
cognitive decline is due solely to atrophy rather than other causes such as a tumor
or trauma (Farran et al., 2011, p. 210). Doctors run multiple tests to confirm the
diagnosis so that patients can be properly cared for, whether that means moving in
with a family member, regularly visiting a neurologist, or relocating to a nursing

home. By increasing the general public’s awareness of these symptoms,
Alzheimer’s disease patients will live a safer life of better quality.
SYMPTOM PROGRESSION
Since Alzheimer’s disease is irreversible, symptoms only worsen with time;
however, new symptoms can manifest depending on the stage and severity of the
illness. According to Jost et al. (1996), “Psychiatric manifestations of depression
occurred more than 2 years before diagnosis… Psychotic symptoms manifested
around the time of diagnosis… whereas agitative symptoms occurred in the first
year after diagnosis” (p. 1078). This explains how Alzheimer’s disease typically
begins with depression and psychotic symptoms but can later be characterized by
aggression and irritability as it progresses. As the illness advances from early- to
late-stage, these cognitive changes only become more apparent and warrant the
need for professional care. Surprisingly, the progression of this illness occurs at a
faster rate than expected due to such rapid brain deterioration; the temporal lobe of
an Alzheimer’s patient declines at a rate of 15.1% per year while that of a healthy
person is only 1.5% (Jobst and Grossberg, 1994, p. 829). Not only are these
symptoms severe, but they also must be recognized as early as possible since
waiting for even a short period of time can significantly worsen the prognosis for
an Alzheimer’s disease patient.

LITERATURE REVIEW
Due to a lack of public awareness of general aspects of Alzheimer’s disease since
its symptoms are so similar to that of regular aging, numerous recent works discuss
these components in order to share valuable information about the internal
symptoms, progression, and external signs of Alzheimer’s disease (Alzheimer’s
Association, 2012, p. 6). For instance, Thies and Bleiler (2011) describe the
diagnostic criteria, warning signs, general prognosis, and typical characteristics of
Alzheimer’s disease while Jost and Grossberg (1996) chronicle psychiatric changes
in Alzheimer’s disease patients as the illness worsens from early- to late-stage.
Furthermore, the fourth edition of the Diagnostic and Statistical Manual of Mental
Disorders (2000) details the criteria for an Alzheimer’s disease diagnosis by a
medical professional, informing readers of the overarching themes of Alzheimer’s
disease and what to screen for in potential patients.
There are many hypotheses surrounding the neuroscience behind
Alzheimer’s disease and its physiological causes. For example, Bancher et al.
(1989) explore Alzheimer’s disease etiology by discussing the potentially harmful
neurological effects of neurofibrillary tangles in the brain, which lead to memory
loss and neuronal cell damage. In comparing brain tissue in patients with
Alzheimer’s disease to that of control cases without dementia postmortem, they
found numerous neurofibrillary tangles located in spaces typically occupied by

healthy neurons in Alzheimer’s disease patients, supporting that significant
cognitive decline in this illness correlates with the growth of these substances due
to resulting neuronal damage. Alternatively, Killiany et al. (1993) investigates the
contribution of temporal lobe atrophy to Alzheimer’s disease development using
magnetic resonance imaging (MRI) to compare the brains of Alzheimer’s disease
patients to that of healthy controls of the same age to determine which parts of the
brain are compromised with disease progression. These researchers explore the
same theory as Jobst et al. (1994), who detail the rate at which brain tissue changes
in Alzheimer’s disease and how the temporal lobe affected in particular. Studies
surrounding the temporal lobe’s role in Alzheimer’s disease differs from that of
neurofibrillary tangles because they are conducted antemortem, meaning that the
researchers studied living patients to examine temporal lobes atrophy while
neurofibrillary tangles were observed postmortem. Lastly, Hardy and Selkoe
(2002) examine the potential for plaque aggregation in the brain to induce
Alzheimer’s disease by detailing this hypothesis’ successes as well as
shortcomings. Known as amyloid plaques, these detrimental substances are
prominent Alzheimer’s disease patients, leading researchers to believe that these
aggregates might be an underlying cause of this illness. However, they also note
that this theory is under criticism since the number of amyloid plaques in the brain
does not correlate with Alzheimer’s disease severity, leading scientists to think that
amyloid plaques might contribute only to its onset rather than progression. Each of
these works focus on different hypotheses that explain potential physiological
causes of Alzheimer’s disease and how this illness develops within the brain over
time.

DISCUSSION
This section of research and analysis explores the three most prevalent hypotheses
surrounding the role of neuroscience in Alzheimer’s disease, including the temporal
lobe hypothesis, neurofibrillary tangles hypothesis, and amyloid plaque hypothesis.
While they address different potential etiologies of Alzheimer’s disease, they are
closely related and together, highlight how the onset of this illness can affect
multiple regions of the brain and contribute to cognitive decline.
TEMPORAL LOBE HYPOTHESIS
One theory regarding physiological causes of Alzheimer’s disease postulates that
temporal lobe atrophy leads to cognitive decline and subsequent memory loss.
According to Killiany et al. (1993), “significant abnormality can be found in the
temporal lobe of patients with only mild symptoms of AD,” meaning that the onset
of this disease can be marked in part by temporal lobe deterioration and the loss of
neurons in this region of the brain can explain the lack of communication between
neurons that allow for memory recall (p. 952). Determining where Alzheimer’s

disease originates within the brain would allow for direct treatment; for instance, if
medical professionals know that cognitive decline characteristic of Alzheimer’s
disease begins with temporal lobe atrophy, then they could immediately target this
specific brain region for patients in the earlier stages of Alzheimer’s disease.
Moreover, Pettigrew et al. (2017) investigate both temporal lobe atrophy’s
relationship with Alzheimer’s disease in its asymptomatic preclinical phase as well
as the presence of biomarkers that might lead to temporal lobe atrophy itself. They
found that high levels of amyloid plaques—further discussed later in this review—
and p-tau proteins were associated with the greatest temporal lobe atrophy, but not
the rate of atrophy, in both healthy controls and preclinical Alzheimer’s disease
patients; however, Alzheimer’s disease patients experienced higher levels of both
amyloid and p-tau in addition to subsequent temporal lobe atrophy (p. 442). These
findings allow medical professionals to use brain-imaging technology to diagnose
patients with Alzheimer’s disease before it progresses by looking for decay in the
temporal lobe as well as perform protein assays to determine amyloid and p-tau
presence in this region. The ability to immediately diagnose Alzheimer’s disease
will not only allow for better patient care through early intervention, but also let
researchers and physicians visualize changes in the brain over time with
Alzheimer’s disease onset by following patients from early- to late-stages.
NEUROFIBRILLARY TANGLES HYPOTHESIS
Another theory that addresses neural decay with Alzheimer’s disease states that a
buildup of neurofibrillary tangles—abnormal clusters that aggregate and fill the
space that originally contained a healthy neuron—physically block and inhibit
communication between neurons. As Alzheimer’s disease progresses, these tangles
grow in size and become increasingly damaging to memory and cognitive function.
Bancher et al. (1989) explains that early tangles (Stage 1) are delicate bundles of
fiber in the temporal lobe, which then mutate into mature tangles (Stage 2) that
bundle together and can fill the entire neuron’s cytoplasm, causing the nucleus to
either shrink or dislocate. Lastly, in the final stage (Stage 3), they become large,
loosely arranged bundles freely located without any connection to a neuron and are
known as “ghost tangles”. In this stage, the neuron dies, and bundles move into the
space originally occupied by the affected neuron (pp. 93-4). As these tangles grow
and kill off working neurons in the brain, neuronal signals in that region eventually
stop altogether due to a lack of healthy neurons available for communication.
Furthermore, Lewis et al. (2000) note that “neurofibrillary tangles (NFT) composed
of the microtubule-associated protein tau are prominent in Alzheimer disease
(AD)… Mutations in the gene (Mtapt) encoding tau protein cause frontotemporal
dementia… thereby proving that tau dysfunction can directly result in
neurodegeneration” (p. 402). This finding directly relates to the temporary lobe
atrophy hypothesis in the tau protein’s role in neuronal damage and resulting

cognitive decline in Alzheimer’s disease patients. Detecting tau-protein associated
neurofibrillary tangles in the beginning stages of Alzheimer’s disease could allow
for the early medical intervention necessary to slow its progression; using
neuroimaging techniques to locate these tangles in a specific brain region would
allow for treatment directly targeting bundles of neurofibrillary tangles to slow or
even reverse Alzheimer’s disease progression.
AMYLOID PLAQUE HYPOTHESIS
Another theory investigating Alzheimer’s disease etiology posits that an adhesive
substance known as Amyloid β-peptide (Aβ) forms plaques in the brain caused by
random mutations in the gene coding for amyloid precursor protein (APP), leading
to senility and memory loss. As Aβ accumulates in the synapse, where signals travel
from neuron to neuron, allowing for various cognitive functions such as
memorization and speaking (Hardy and Selkoe, 2002, pp. 353-4). When these
plaques block the synapse, neurons are unable to communicate due to the loss of
physical gaps available for signal transmission. This idea is further supported by
the neurofibrillary tangles hypothesis in that Hardy and Selkoe (2002) note previous
studies observing that mice that overexpressed the mutant APP gene experienced
significant Aβ plaque buildup before neurofibrillary tangles formation, meaning
that Alzheimer’s disease most likely stems from an APP gene mutation leading to
senile plaques in synapses between neurons that accumulate over time, eventually
forming neurofibrillary tangles that kill and replace neurons. However, there are
concerns with this hypothesis due to a lack of correlation between the number of
amyloid plaques in the brain and severity of cognitive decline in Alzheimer’s
disease patients (p. 353). In other words, the amount of Aβ plaques in the brain is
unrelated to degree of senility in Alzheimer’s disease patients, making it difficult
to eventually establish a causal relationship between these variables. If researchers
can identify the cause of APP gene mutations and understand the association
between Aβ plaques and Alzheimer’s disease onset, then there would be potential
for a preventative treatment inhibiting Aβ plaque buildup before it interferes with
cognitive function.

CONCLUSION
Despite the overwhelmingly large number of patients and families burdened by
Alzheimer’s disease, most are unaware of the scientific findings behind its
biological, physical, and emotional symptoms. It is vital to increase understanding
of these relationships between neurology and Alzheimer’s disease because it will
not only inform them of the signs and symptoms to look for, but also allow them to
obtain better patient care and increase quality of life for either themselves or an
affected loved one through primary and secondary prevention. Additionally,
educating the general population about this concept can also motivate other

researchers to further investigate potential underlying causes of and treatments for
Alzheimer’s disease.
The exact link between neuroscience and Alzheimer’s disease has yet to be
fully understood. While significant progress has been made, researchers and
medical professionals are still exploring the etiology and progression of this illness.
However, the temporal lobe, neurofibrillary tangles, and amyloid plaque
hypotheses shed light on potentially promising treatments that involve directly
targeting certain brain regions and could lead to an eventual cure. If researchers
learn where specifically in the brain to attack Alzheimer’s disease, medical
professionals can then intervene with or even prevent its onset by knowing exactly
where to look for neurological and physiological signs of Alzheimer’s disease
before it is too late.
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